Suppression of in vitro IgM rheumatoid factor production by diphtheria toxin interleukin 2 recombinant fusion protein (DAB 486IL-2) in patients with refractory rheumatoid arthritis

Autor: R E, Schrohenloher, W J, Koopman, T G, Woodworth, L W, Moreland

Publikováno v: The Journal of rheumatology. 23(11)

To investigate the effect of diphtheria toxin interleukin 2 recombinant fusion protein (DAB 486IL-2) on in vitro synthesis of immunoglobulin and rheumatoid factor (RF) in patients with severe refractory rheumatoid arthritis (RA) enrolled in a phase I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bdf7f25202c0eba31746f2a0034975f3
https://pubmed.ncbi.nlm.nih.gov/8923354

Early clinical studies of IL-2 fusion toxin in patients with severe rheumatoid arthritis and recent onset insulin-dependent diabetes mellitus

Autor: T G, Woodworth

Publikováno v: Clinical and experimental rheumatology. 11

DAB486IL-2 is the first of a new class of targeted biologicals called fusion toxins. This agent is an interleukin-2 receptor (IL-2R)-targeted cytotoxin which kills activated IL-2R-expressing lymphocytes at 10(-10) M concentrations. Since activated ly

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8e8b7eb880bc3a9d6b4e9cb071e37cba
https://pubmed.ncbi.nlm.nih.gov/8324945

Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules

Autor: Vicki Rubin Kelley, T. G. Woodworth, J. R. Murphy, Nichols Jc, Terry B. Strom

Publikováno v: Annual review of medicine. 44

With the exception of certain hematologic malignancies, the high affinity interleukin-2 (IL-2) receptor is only transiently expressed during the brief antigen-triggered proliferative burst of lymphocytes. Hence, we wondered whether administration of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fad7332283e23c7e44c9e2b771258b3
https://pubmed.ncbi.nlm.nih.gov/8476255

Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group.

Autor: Nielsen SM; Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark sabrina.mai.nielsen@regionh.dk.; Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark., Uggen Rasmussen M; Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark., Boers M; Department of Epidemiology & Data Science; and Amsterdam Rheumatology and Immunology Center, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands., A van der Windt D; School of Medicine; Primary Care Centre Versus Arthritis; and Centre for Prognosis Research, Faculty of Medicine and Health Sciences, Keele University, Keele, Staffordshire, UK., de Wit M; OMERACT Patient Research Partner, Amsterdam, The Netherlands., G Woodworth T; Division of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles, California, USA., A Flurey C; Department of Health and Social Sciences, Faculty of Health and Applied Sciences, University of the West of England, Bristol, UK., Beaton D; Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada., Shea B; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Escorpizo R; Department of Rehabilitation and Movement Science, College of Nursing and Health Sciences, University of Vermont, Burlington, Vermont, USA.; Swiss Paraplegic Research, Nottwil, Switzerland., Furst DE; Division of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.; Division of Rheumatology, University of Washington, Seattle, Washington, USA.; University of Florence, Florence, Italy., Smolen JS; Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria., Toupin-April K; Children's Hospital of Eastern Ontario Research Institute; Department of Pediatrics and School of Rehabilitation Sciences, University of Ottawa, Ottawa, Ontario, Canada., Boonen A; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+, Maastricht, The Netherlands.; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands., Voshaar M; University of Twente, Enschede, Faculty of Behavioural Management and Social sciences, Department Psychology, Health and Technology, University of Twente, Enschede, The Netherlands., Ellingsen T; Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark., Wells GA; School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada., Reeves BC; Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, UK., March L; Florance and Cope Professorial Department of Rheumatology, Royal North Shore Hospital and Institute of Bone and Joint Research, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia., Tugwell P; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada., Christensen R; Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark.; Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark.

Publikováno v: Annals of the rheumatic diseases [Ann Rheum Dis] 2021 Feb; Vol. 80 (2), pp. 242-249. Date of Electronic Publication: 2020 Oct 14.